Holen Sie sich die Stockscreener-App
36.67
0.84%
-0.31
Handel nachbörslich:
36.66
-0.01
-0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$36.98
Offen:
$37
24-Stunden-Volumen:
11.45M
Relative Volume:
0.49
Marktkapitalisierung:
$162.76B
Einnahmen:
$46.77B
Nettoeinkommen (Verlust:
$15.45B
KGV:
10.57
EPS:
3.468
Netto-Cashflow:
$4.40B
1W Leistung:
+3.91%
1M Leistung:
-4.95%
6M Leistung:
-38.52%
1J Leistung:
-41.37%
1-Tages-Spanne:
$36.52
$37.42
1-Wochen-Bereich:
$35.32
$37.42
52-Wochen-Spanne:
$35.12
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
36.67 | 164.13B | 46.77B | 15.45B | 4.40B | 3.468 |
LLY
Lilly Eli Co
|
927.06 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.97 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.69 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.83 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.85 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-18 | Eingeleitet | Bernstein | Outperform |
| 2026-03-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-03-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Herabstufung | Goldman | Buy → Neutral |
| 2026-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Kepler | Buy → Hold |
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Hochstufung | Jefferies | Underperform → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Novo Nordisk A/ S stock: Weight-loss boom far from over — what investors need to know - AD HOC NEWS
Nuclear, Pharma and Travel Buybacks: Confident or Cautious Signals? - Investing.com
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus - Sahm
NVO Forecast, Price Target & Analyst Ratings | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan - Sahm
Novo Nordisk (NYSE: NVO) details progress on DKK 15bn share repurchase - Stock Titan
Novo Nordisk A/S Stock: Pipeline Innovations Amid Share Price Pressures and Market Challenges - AD HOC NEWS
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program - Sahm
Novo Nordisk A/S Stock: FDA Approval for Awiqli Bolsters Diabetes Portfolio Amid 2026 Market Recover - AD HOC NEWS
Novo Nordisk A/S Stock: Recent AGM Resolutions Reinforce Dual-Class Structure and Dividend Strength - AD HOC NEWS
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk A/S stock faces pressure amid shifting obesity drug landscape and analyst hold rating - AD HOC NEWS
Novo Nordisk A/S stock faces analyst scrutiny amid Wegovy demand questions and Equal Weight rating h - AD HOC NEWS
Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures - AD HOC NEWS
NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Sahm
Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS
Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS
Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - AD HOC NEWS
Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS
FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm
Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - sahmcapital.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - Finansavisen
Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz
Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.73%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):